In-depth mutation and SNP discovery using DHPLC gene scanning

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 2, 2003, Pages 237-252

  Lilleberg, Stan L ^a  

^a TRANSGENOMIC INC   (United States)

Author keywords

Candidate gene; DHPLC; DNA methylation; Drug metabolism; Drug resistance; Genetic variant; Mutation; Pharmacogenetics; SNP discovery; SNP validation; Somatic mutation

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 8; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; GAMMA SECRETASE; IMATINIB; LOW DENSITY LIPOPROTEIN RECEPTOR; MYOSIN; NEW DRUG; NICASTRIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRESENILIN 1; PRESENILIN 2; PROTEIN RET; RNA; THIOPURINE METHYLTRANSFERASE; VASCULOTROPIN;

ALZHEIMER DISEASE; ANOPHTHALMIA; AUTOIMMUNE DISEASE; BETA THALASSEMIA; CANCER; CENTRONUCLEAR MYOPATHY; CONGENITAL DISORDER OF GLYCOSYLATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DRUG METABOLISM; DRUG RESISTANCE; ESSENTIAL HYPERTENSION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC VARIABILITY; HEARING IMPAIRMENT; HEMOPHILIA A; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY POLYCYSTIC DISEASE; LEBER CONGENITAL AMAUROSIS; LONG QT SYNDROME; MELANOMA; MENTAL DISEASE; MICROPHTHALMIA; MULTIPLE SCLEROSIS; NETHERTON DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOONAN SYNDROME; OCULAR ALBINISM; OPEN ANGLE GLAUCOMA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHENOTYPE; RETINA MACULA DEGENERATION; RETINITIS PIGMENTOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; SPINAL MUSCULAR ATROPHY; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; WILSON DISEASE; WOLFRAM SYNDROME;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA METHYLATION; DRUG RESISTANCE; GENE THERAPY; HUMANS; MUTATION; NUCLEIC ACID DENATURATION; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0037344681     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Dollery CT: Drug discovery and development in the molecular era. Br J Clin Pharmacol (1999) 47:5-6.
2. Jazwinska EC: Exploiting human genetic variation in drug discovery and development. Drug Disc Today (2001) 6:198-205.
3. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science (1999) 286:487-491.
4. Waring JF, Halbert DN: The promise of toxicogenomics. Curr Opin Mol Ther(2002) 4:229-235.
5. Johnson JA, Evans WE: Molecular diagnostics as a predictive tool: Genetics of drug efficacy and toxicity. Trends Mol Med (2002) 8:300-305.
6. Xiao W, Oefner PJ: Denaturing high-performance liquid chromatography: A review. Hum Mutat (2001) 17:439-474. An outstanding comprehensive review of DHPLC technology and the various genetic applications.
7. Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, Tavtigian SV, Nathanson KL, Ostrander E, Frank TS; Steering Committee of the Breast Cancer Information Core (BIC) Consortium: Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet (2001) 38:824-833. A report of a blinded study describing the thorough assessment of various mutation detection methodologies and the high accuracy of DHPLC.
8. Ravnik-Glavač M, Atkinson A, Glavač D, Dean M: DHPLC screening of cystic fibrosis gene mutations. Hum Mutat (2002) 19:374-383. This paper describes the screening of the CFTR gene (23 exons) by DHPLC, with an accuracy of 100% for mutations tested.
9. Takashima H, Boerkoel CF, Lupski JR: Screening for mutations in a genetically heterogeneous disorder: DHPLC versus DNA sequence for mutation detection in multiple genes causing Charcot-Marie-Tooth neuropathy. Genet Med (2001) 3:335-342. A report demonstrating the utility of complete DHPLC mutation scanning of multiple genes associated with a single genetic disorder. Several novel mutations, missed by direct DNA sequencing, were discovered.
10. Kwok PY, Deng Q, Zakeri H, Taylor SL, Nickerson DA: Increasing the information content of STS-based genome maps: Identifying polymorphisms in mapped STSs. Genomics (1996) 31:123-126.
11. Jones AC, Sampson JR, Cheadle JP: Low level mosaicism detectable by DHPLC but not by direct sequencing. Hum Mutat (2001) 17:233-234. Low-level mutations in heterogeneous samples, which cannot be identified by direct DNA sequencing, were identified by DHPLC. Somatic mosaicism was observed in TSC1 and TSC2 genes from tuberous sclerosis patients.
12. Antonarakis ES, Sampson JR, Cheadle JP: Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2. J Biochem Biophys Methods (2002) 51:161-164. This paper describes the DHPLC-detection of germ-line and somatic mutations in TSC2 gene. Somatic mutations were observed in peripheral blood lymphocytes.
13. Leonard DG, Travis LB, Addya K, Dores GM, Holowaty EJ, Bergfeldt K, Malkin D, Kohler BA, Lynch CF, Wiklund T et al: p53 Mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res (2002) 8:973-985.
14. van Den Bosch BJ, de Coo RF, Scholte HR, Nijland JG, Van Den Bogaard R, de Visser M, de Die-Smulders CE, Smeets HJ: Mutation analysis of the entire mitochondrial genome using denaturing high performance liquid chromatography. Nucleic Acids Res (2000) 28:E89. This article shows the complete mutation scanning of the mitochondrial genome by DHPLC, and detection of heteroplasmy at levels as low as 0.5%, which can be important in various pathogenic processes.
15. Youssoufian H, Pyeritz RE: Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet (2002) 3:748-758.
16. Lipkin SM, Wang V, Stoler DL, Anderson GR, Kirsch I, Hadley D, Lynch HT, Collins FS: Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. Hum Mutat (2001) 17:389-396. Somatic mutations are detected by DHPLC in a novel DNA mismatch repair gene associated with colorectal cancer.
17. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ. Coxhead J, Garner RC, Steele RJ, Wolf CR: Mutations in APC, Kirsten-ras, and p53: Alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA (2002) 99:9433-9438. An efficient scanning of a large gene, with no true hot spots (APC) for both known and unknown variations by DHPLC, is described.
18. Lewin B: The mystique of epigenetics. Cell (1998) 93:301-303.
19. Bird A: DNA methylation de novo. Science (1999) 286:2287-2288.
20. Novik KL, Nimmrich I, Genc B, Maier S, Piepenbrock C, Olek A, Beck S: Epigenomics: Genome-wide study of methylation phenomena. Curr Issues Mol Biol (2002) 4:111-128.
21. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet (1999) 21:163-167.
22. Engemann S, Strodicke M, Paulsen M, Franck O, Reinhardt R, Lane N, Reik W, Walter J: Sequence and functional comparison in the Beckwith-Wiedemann region: Implications for a novel imprinting centre and extended imprinting. Hum Mol Genet (2000) 9:2691-2706.
23. Jiang Y, Tsai TF, Bressler J, Beaudet AL: Imprinting in Angelman and Prader-Willi syndromes. Curr Opin Genet Dev (1998) 8:334-342.
24. Friso S, Choi SW: Gene-nutrient interactions and DNA methylation. J Nutr (2002) 132:2482S-2387S.
25. Johanning GL, Heimburger DC, Piyathilake CJ: DNA methylation and diet in cancer. J Nutr(2002) 132:3814S-3818S.
26. Deng D, Deng G, Smith MF, Zhou J, Xin H, Powell SM, Lu Y: Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res (2002) 30:E13. A PCR-DHPLC-based method for simultaneous detection of methylation and sequence variations is described. This methodology was used to examine the hMLH1 and COX-2 promoters.
27. Baumer A, Wiedemann U, Hergersberg M, Schinzel A: A novel MSP/DHPLC method for the investigation of methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum Mutat(2001) 17:423-430. This paper reports the evaluation of DNA methylation status using DHPLC, and describes the identification of somatic cell mosaicisms that are not detectable with other technologies.
28. Baumer A: Analysis of the methylation status of imprinted genes based on methylation-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. Methods (2002) 27:139-143.
29. El-Maarri O, Herbiniaux U, Walter J, Oldenburg J: A rapid, quantitative, non-radioactive bisulfite-SNuPE-IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res (2002) 30:E25. The assessment of specific CpG methylation sites using primer extension combined with DHPLC analysis as an automated approach is presented.
30. Matin MM, Baumer A, Hornby DP: An analytical method for the detection of methylation differences at specific chromosomal loci using primer extension and ion pair reverse phase HPLC. Hum Mutat (2002) 20:305-311.
31. Syvanen AC: Accessing genetic variation: Genotyping single nucleotide polymorphisms. Nat Rev Genet (2001) 2:930-942.
32. Nairz K, Stocker H, Schindelholz B, Hafen E: High-resolution SNP mapping by denaturing HPLC. Proc Natl Acad Sci USA (2002) 99:10575-10580. The fine mapping of SNPs associated with candidate genes by DHPLC scanning, avoiding unnecessary DNA sequencing is presented.
33. Lynch RA, Wagoner L, Li S, Sparks L, Molkentin J, Dorn GW: Novel and nondetected human signaling protein polymorphisms. Physiol Genomics (2002) 10:159-168. The discovery of novel SNPs that are not present in various SNP databases, such as NCBI and Celera, is presented. Also, a significant number of dsSNPs were not present in the patient cohorts. This study emphasizes the need to validate dsSNPs prior to assessing patient cohorts or conducting large population studies, and presents DHPLC as a reliable and cost-effective technology for SNP validation.
34. Small KM, Seman CA, Castator A, Brown KM, Liggett SB: False positive non-synonymous polymorphisms of G-protein coupled receptor genes. FEBS Lett (2002) 516:253-256.
35. Collins FS, Guyer MS, Chakravarti A: Variations on a theme: Cataloging human DNA sequence variation. Science (1997) 278:1580-1581.
36. Lander ES: The new genomics: Global views of biology. Science (1996) 274:536-539.
37. Risch NJ: Searching for genetic determinants in the new millennium. Nature (2000) 405:847-856.
38. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N et al: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 22:231-238.
39. Glatt CE, DeYoung JA, Delgado S, Service SK, Giacomini KM, Edwards RH, Risch N, Freimer NB: Screening a large reference sample to identify very low frequency variants: Comparisons between two genes. Nat Genet (2001) 27:435-438. This paper describes the identification of specific patterns of genetic variation associated with gene function by initial DHPLC scanning for very low frequency mutations in coding regions and splice junctions.
40. Martin ER, Gilbert JR, Lai EH, Riley J, Rogala AR, Slotterbeck BD, Sipe CA, Grubber JM, Warren LL, Conneally PM et al: Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics (2000) 63:7-12.
41. Luedecking-Zimmer E, DeKosky ST, Chen Q, Barmada MM, Kamboh MI: Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum Genet (2002) 111:443-451.
42. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song YQ, Rogaeva E, Chen F, Kawarai T et al: Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature (2000) 407:48-54.
43. Dermaut B, Theuns J, Sleegers K, Hasegawa H, Van den Broeck M, Vennekens K, Corsmit E, St George-Hyslop P, Cruts M, van Duijn CM, Van Broeckhoven C: The gene encoding nicastrin, a major γ-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am J Hum Genet (2002) 70:1568-1574.
44. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ: Prevalence and age-dependence of malignant mutations in the β-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. J Am Coll Cardiol (2002) 39:2042-2048.
45. Blair E, Redwood C, de Jesus Oliveira M, Moolman-Smook JC, Brink P, Corfield VA, Ostman-Smith I, Watkins H: Mutations of the light meromyosin domain of the β-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ Res (2002) 90:263-269.
46. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H: Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet (2001) 10:1215-1220.
47. Blair E, Price SJ, Baty CJ, Ostman-Smith I, Watkins H: Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy. J Med Genet (2001) 38:385-388.
48. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B et al: Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet (2001) 10:189-194.
49. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 11:961-969.
50. Lie BA, Akselsen HE, Bowlus CL, Gruen JR, Thorsby E, Undlien DE: Polymorphisms in the gene encoding thymus-specific serine protease in the extended HLA complex: A potential candidate gene for autoimmune and HLA-associated diseases. Genes Immunity (2002) 3:306-312.
51. Bitoun E, Chavanas S, Irvine AD, Lonie L, Bodemer C, Paradisi M, Hamel-Teillac D, Ansai S, Mitsuhashi Y, Taieb A et al: Netherton syndrome: Disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol (2002) 118:352-361.
52. Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP et al: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet (1999) 36:228-232.
53. Audrezet MP, Chen JM, Le Marechal C, Ruszniewski P, Robaszkiewicz M, Raguenes O, Quere I, Scotet V, Ferec C: Determination of the relative contribution of three genes - the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene - to the etiology of idiopathic chronic pancreatitis. Eur J Hum Genet (2002) 10:100-106.
54. Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol Med (2001) 7:201-204.
55. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB: A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem (2002) 306:63-73. This report emphasizes the pharmacogenetic value of identifying allelic variants, and uses DHPLC to quickly scan the DPYD gene for mutations associated with 5-FU toxicity.
56. Coulthard SA, Hall AG: Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics (2001) 1:254-261.
57. Evans WE: Thiopurine S-methyltransferase: A genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics (2002) 12:421-423.
58. Schaeffeler E, Lang T, Zanger UM, Eicheibaum M, Schwab M: High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem (2001) 47:548-555. A study describing a rapid and efficient method for genotyping relevant TPMT mutations using DHPLC, while simultaneously screening for novel genetic variability in the TPMT gene.
59. Pfeiffer RM, Bura E, Smith A, Rutter JL: Two approaches to mutation detection based on functional data. Stat Med (2002) 21:3447-3464.
60. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125. Multiple mutations in the BCR-ABL kinase active site domain confer resistance to the cancer drug imatinib. The mutational status of a tumor can provide insight for clinical approaches to therapy.
61. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol (2002) 160:1567-1572. The detection of mutations in a gene encoding the tyrosine kinase, c-kit, which is a cancer drug target of imatinib and may be a useful indicator of drug resistance, is described.
62. Uthoff SM, Duchrow M, Schmidt MH, Broll R, Bruch H, Strik MW, Galandiuk S: VEGF isoforms and mutations in human colorectal cancer. Int J Cancer (2002) 101:32-36. Novel VEGF splice variants and mutations that appear in the coding regions of all the detected splice variants present in human colorectal tumors are presented. This could have important implications in therapeutic strategies aimed at VEGF targets.
63. Hurtle W, Shoemaker D, Henchal E, Norwood D: Denaturing HPLC for identifying bacteria. Bio Techniques (2002) 33:386-391. The identification of bacteria at the species level, using a PCR-DHPLC-based approach, is described.
64. Shlush LI, Behar DM, Zelazny A, Keller N, Lupski JR, Beaudet AL, Bercovich D: Molecular epidemiological analysis of the changing nature of a meningococcal outbreak following a vaccination campaign. J Clin Microbiol (2002) 40:3565-3571. This paper describes a quick method for bacterial species identification using PCR-DHPLC and MLST.
65. Maiden MC, Bygraves JA, Fell E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA et al: Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA (1998) 95:3140-3145.
66. Eaves DJ, Liebana E, Woodward JM, Piddock LJ: Detection of gyrA mutations in quinolone-resistant Salmonealla enterica by denaturing high-performance liquid chromatography. J Clin Microbiol (2002) 40:4121-4125. This article describes the accurate DHPLC detection of DNA mutations in the Salmonella enterica gyrA gene responsible for quinoline-resistance.
67. Hannachi-M'Zali F, Ambler JE, Taylor CF, Hawkey PM: Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). J Antimicrob Chemother (2002) 50:649-655. Rapid, high-throughput mutation scanning of Staphylococcus aureus genes involved with resistance to quinolines.
68. Cooksey RC, Morlock GP, Holloway BP, Limor J, Hepburn M: Temperature-mediated heteroduplex analysis performed by using denaturing high-performance liquid chromatography to identify sequence polymorphisms in Mycobacterium tuberculosis complex organisms. J Clin Microbiol (2002) 40:1610-1616. DHPLC can be used as a routine genotypic screen for mutations responsible for antituberculosis drug resistance.
69. Doukhan L, Delwart E: Population genetic analysis of the protease locus of human deficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay. J Virol (2001) 75:6729-6736.
70. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Novak MA, Hahn BH et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 373:117-126.
71. Rudolph G, Kalpadakis P, Haritoglou C, Rivera A, Weber BH: Mutations in the ABCA4 gene in a family with Stargardt's disease and retinitis pigmentosa. Klin Monatsbl Augenheilkd (2002) 219:590-596.
72. 2-adrenergic receptor by electronic microchip assay, DHPLC, and direct sequencing. J Hum Genet (2002) 47:500-503.
73. Yamamoto N, Nakayama J, Yamakawa-Kobayashi K, Hamaguchi H, Miyazaki R, Arinami T: Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. Hum Mutat (2002) 19:251-257.
74. Schollen E, Martens K, Geuzens E, Matthijs G: DHPLC analysis as a platform for molecular diagnosis of congenital disorders of glycosylation (CDG). Eur J Hum Genet (2002) 10:643-648.
75. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Lepretre F, Dupont S et al: Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet (2002) 11:2607-2614.
76. Desai PP, Bunker CH, Ukoli FA, Kamboh MI: Genetic variation in the apolipoprotein D gene among African blacks and its significance in lipid metabolism. Atherosclerosis (2002) 163:329-338.
77. Weirich G, Cabras A, Serra S, Coni P, Nurchi A, Faa G, Hofler H: Rapid identification of Wilson's disease carriers by denaturing high-performance liquid chromatography. Prev Med (2002) 35:278-284.
78. LeMarechal C, Audrezet MP, Quere I, Raguenes O, Langonne S, Ferec C: Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high performance liquid chromatography (D-HPLC): Major implications for genetic counselling. Hum Genet (2001) 108:290-298.
79. Ferec C, Rouault K, Audrezet MP, Le Marechal C: Improvement of the scanning of the CFTR gene by multiplexing DHPLC analysis. Am J Hum Genet (2002) 71:S546.
80. Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, Bohlega S, Dotti MT, Federico A, Shizuka M et al: Mutational spectrum of the CHAC gene in patients with choreaacanthocytosis. Eur J Hum Genet (2002) 10:773-781.
81. Morrison D, FitzPatrick D, Hanson I, Williamson K, van Heyningen V, Fleck B, Jones I, Chalmers J, Campbell H: National study of microphthalmia, anophthalmia, and coloboma (MAC) in Scotland: Investigation of genetic aetiology. J Med Genet (2002) 39:16-22.
82. Wu FF, Ryan A, Devaney J, Warnstedt M, Korade-Mirnics Z, Poser B, Escriva MJ, Pegoraro E, Yee AS, Felice KJ et al: Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain (2002) 125:2392-2407.
83. Hanein S, Perrault I, Olsen P, Lopponen T, Hietala M, Gerber S, Jeanpierre M, Barbet F, Ducroq D, Hakiki S et al: Evidence of a founder effect for the RETGC1 (GUCY2D) 2943DeIG mutation in Leber congenital amaurosis pedigrees of Finnish origin. Hum Mutat (2002) 20:322-323.
84. Todd RD, Lobos EA: Mutation screening of the dopamine D2 receptor gene in attention-deficit hyperactivity disorder subtypes: Preliminary report of a research strategy. Am J Med Genet (2002) 114:34-41.
85. Anney RJ, Rees MI, Bryan E, Spurlock G, Williams N, Norton N, Williams H, Cardno A, Zammit S, Jones S et al: Characterisation, mutation detection, and association analysis of alternative promoters and 5' UTRs of the human dopamine D3 receptor gene in schizophrenia. Mol Psychiatry (2002) 7:493-502.
86. Frusconi S, Passerini I, Girolami F, Masieri M, Linari S, Longo G, Morfini M, Torricelli F: Identification of seven novel mutations in F8C by DHPLC. Hum Mutat (2002) 20:231-232.
87. Bogdanova N, Markoff A, Pollmann H, Nowak-Gottl U, Eisert R, Dworniczak B, Eigel A, Horst J: Prevalence of small rearrangements in the Factor VIII gene F8C among patients with severe hemophilia A. Hum Mutat (2002) 20:236-237.
88. Halliday DJ, Hutchinson S, Lonie L, Hurst JA, Firth H, Handford PA, Wordsworth P: Twelve novel FBN1 mutations in Marfan syndrome and Marfan related phenotypes test the feasibility of FBN1 mutation testing in clinical practice. J Med Genet (2002) 39:589-593.
89. Matyas G, De Paepe A, Halliday D, Boileau C, Pals G, Steinmann B: Evaluation and application of denaturing HPLC for mutation detection in Marian syndrome: Identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene. Hum Mutat (2002) 19:443-456.
90. Johnson GC, Payne F, Nutland S, Stevens H, Tuomilehto-Wolf E, Tuomilehto J, Todd JA: A comprehensive, statistically powered analysis of GAD2 in type 1 diabetes. Diabetes (2002) 51:2866-2870.
91. Rickard S, Kelsell DP, Sinmana T, Rajput K, MacArdle B, Bitner-Glindzicz M: Recurrent mutations in the deafness gene GJB2 (connexin 26) in British Asian families. J Med Genet (2001) 38:530-533.
92. Pallares-Ruiz N, Blanchet P, Mondain M, Claustres; M, Roux AF: A large deletion including most of GJB6 in recessive non syndromic deafness: A digenic effect? Eur J Hum Genet (2002) 10:72-76.
93. Williams NM, Bowen T, Spurlock G, Norton N, Williams HJ, Hoogendoorn B, Owen MJ, O'Donovan MC: Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. Mol Psychiatry (2002) 7:508-514.
94. Colosimo A, Guida V, De Luca A, Cappabianca MP, Bianco I, Palka G, Dallapiccola B: Reliability of DHPLC in mutational screening of βglobin (HBB) alleles. Hum Mutat (2002) 19:287-296.
95. Webster MT, Wells RS, Clegg JB: Analysis of variation in the human β-globin gene cluster using a novel DHPLC technique. Mutat Res (2002) 501:99-103.
96. Pissard S, Huynh LT, Martin J, Goossens M: HFE genotyping by amplification refractory mutation system-denaturing HPLC. Clin Chem (2002) 48:769-772.
97. Chakarova CF, Hims MM, Bolz H, Abu-Safieh L, Patel RJ, Papaioannou MG, Inglehearn CF, Keen TJ, Willis C, Moore AT et al: Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet (2002) 11:87-92.
98. Rugg EL, Common JE, Wilgoss A, Stevens HP, Buchan J, Leigh IM, Kelsell DP: Diagnosis and confirmation of epidermolytic palmoplantar keratoderma by the Identification of mutations in keratin 9 using denaturing high-performance liquid chromatography. Br J Dermatol (2002) 146:952-957.
99. Jongbloed R, Marcelis C, Velter C, Doevendans P, Geraedts J, Smeets H: DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat (2002) 20:382-391.
100. Farook VS, Hanson RL, Wolford JK, Bogardus C, Prochazka M: Molecular analysis of KCNJ10 on 1q as a candidate gene for type 2 diabetes in Pima Indians. Diabetes (2002) 51:3342-3346.
101. Wang Z, Li H, Moss AJ, Robinson J, Zareba W, Knilans T, Bowles NE, Towbin JA: Compound heterozygous mutations in KvLQT1 cause Jervell and Lange-Nielsen syndrome. Mol Genetics Metab (2002) 75:308-316.
102. Bodamer OA, Bercovich D, Schlabach M, Ballantyne C, Zoch D, Beaudet AL: Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin Chem (2002) 48:1913-1918.
103. Bunn CF, Lintott CJ, Scott RS, George PM: Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum Mutat (2002) 19:311.
104. Richter-Unruh A, Martens JW, Verhoef-Post M, Wessels HT, Kors WA, Sinnecker GH, Boehmer A, Drop SL, Toledo SP, Brunner HG et al: Leydig cell hypoplasia: Cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol (2002) 56:103-112.
105. Su Z, Zhang S, Nebert DW, Zhang L, Huang D, Hou Y, Liao L, Xiao C: A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity. J Lipid Res (2002) 43:1595-1601.
106. D'Alfonso S, Mellai M, Giordano M, Pastore A, Malferrari G, Naldi P, Repice A, Liguori M, Cannoni S, Milanese C et al: Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene and study of their association with multiple sclerosis. J Neuroimmunol (2002) 126:196-204.
107. Miraglia Del Giudice E, Cirillo G, Nigro V, Santoro N, D'Urso L, Raimondo P, Cozzolino D, Scafato D, Perrone L: Low frequency of melanocortin-4 receptor (MC4R) mutations in a Mediterranean population with early-onset obesity. Int J Obesity Relat Metab Disord (2002) 26:647-651.
108. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE et al: Mutation screening of the macrophage migration inhibitory factor gene: Positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum (2002) 46:2402-2409.
109. Devaney JM, Donarum EA, Brown KM, Meyer J, Stober G, Lesch KP, Nestadt G, Stephan DA, Pulver AE: No missense mutation of WKL1 in a subgroup of probands with schizophrenia. Mol Psychiatry (2002) 7:419-423.
110. Flex E, De Luca A, D'Apice MR, Buccino A, Dallapiccola B, Novelli G: Rapid scanning of myotubularin (MTM1) gene by denaturing high-performance liquid chromatography (DHPLC). Neuromuscular Disord (2002) 12:501-505.
111. Cobb CJ, Scott G, Swingler RJ, Wilson S, Ellis J, MacEwen CJ, McLean WH: Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. Br J Ophthalmol (2002) 86:191-195.
112. Venken K, Di Maria E, Bellone E, Balestra P, Cassandrini D, Mandich P, De Jonghe P, Timmerman V, Svaren J: Search for mutations in the EGR2 corepressor proteins, NAB1 and NAB2, in human peripheral neuropathies. Neurogenetics (2002) 4:37-41.
113. Hattori M, Kunugi H, Akahane A, Tanaka H, Ishida S, Hirose T, Morita R, Yamakawa K, Nanko S: Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet (2002) 114:304-309.
114. Hedge M, Lewis RA, Richards CS: Diagnostic DNA testing for X-linked ocular albinism (OA1) with a hierarchical mutation screening protocol. Genet Test (2002) 6:7-14.
115. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the μ-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat (2002) 19:459-460.
116. Wilkie H, Osei-Lah A, Chioza B, Nashef L, McCormick D, Asherson P, Makoff AJ: Association of μ-opioid receptor subunit gene and idiopathic generalized epilepsy. Neurology (2002) 59:724-728.
117. Bray NJ, Kirov G, Owen RJ, Jacobsen NJ, Georgieva L, Williams HJ, Norton N, Spurlock G, Jones S, Zammit S et al: Screening the human protcadherin 8 (PCDH8) gene in schizophrenia. Genes Brain Behavior (2002) 1:187-191.
118. Rossetti S, Chauveau D, Walker D, Saggar-Malik A, Winearls CG, Torres VE, Harris PC: A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int (2002) 61:1588-1599.
119. Onuchic LF, Furu L, Nagasawa Y, Hou X, Eggermann T, Ren Z, Bergmann C, Senderek J, Esquivel E, Zeltner R et al: PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexintranscription-factor domains and parallel β-helix 1 repeats. Am J Hum Genet (2002) 70:1305-1317.
120. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M et al: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 30:259-269.
121. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A et al: PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet (2002) 70:1555-1563.
122. Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns JP: PTPN11 mutations in LEOPARD syndrome. J Med Genet (2002) 39:571-574.
123. Sutomo R, Akutsu T, Takeshima Y, Nishio H, Sadewa AH, Harada Y, Matsuo M: Rapid SMN1 deletion test using DHPLC to screen patients with spinal muscular atrophy. Am J Med Genet (2002) 113:225-226.
124. Lam CW, Li CK, Lai CK, Tong SF, Chan KY, Ng GS, Yuen YP, Cheng AW, Chan YW: DNA-based diagnosis of isolated sulfite oxidase deficiency by denaturing high-performance liquid chromatography. Mol Genetics Metab (2002) 75:91-95.
125. Bernassola F, Federici M, Corazzari M, Terrinoni A, Hribal ML, De Laurenzi V, Ranalli M, Massa O, Sesti G, McLean WH et al: Role of transglutaminase 2 in glucose tolerance: Knockout mice studies and a putative mutation in a MODY patient. FASEB J (2002) 16:1371-1378.
126. Dode C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J, Lecron JC, Reinert P, Cattan D, Piette JC et al: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2002) 46:2181-2188.
127. Roberts PS, Chung J, Jozwiak S, Dabora SL, Franz DN, Thiele EA, Kwiatkowski DJ: SNP identification, haplotype analysis, and parental origin of mutations in TSC2. Hum Genet (2002) 111:96-101.
128. Weirich G, Klein B, Wohl T, Engelhardt D, Brauch H: VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endocrinol Metab (2002) 87:5241-5246.
129. Colosimo A, Guida V, Rigoli L, Di Bella C, De Luca A, Palka G, Salpietro DC, Dallapiccola B: Mutational screening of Italian Wolfram syndrome patients by DHPLC. Am J Hum Genet (2002) 71:S385.
130. Wu G, Wu W, Hegde M, Fawkner M, Chong B, Love D, Su LK, Lynch P, Snow K, Richards CS: Detection of sequence variations in the adenomatous polyposis coli (APC) gene using denaturing high-performance liquid chromatography. Genet Test (2001) 5:281-290.
131. Gavert N, Yaron Y, Naiman T, Bercovich D, Rozen P, Shomrat R, Legum C, Orr-Urtreger A: Molecular analysis of the APC gene in 71 Israeli families: 17 Novel mutations. Hum Mutat (2002) 19:664.
132. Jones S, Emmerson P, Maynard J, Best JM, Jordan S, Williams GT, Sampson JR, Cheadle JP: Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations. Hum Mol Genet (2002) 11:2961-2967.
133. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR et al: Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet (2002) 30:227-232.
134. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys (2002) 52:606-613.
135. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI et al: Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene (2002) 21:4863-4871.
136. Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, Lee SY, Kim KH, Shin Y, Noh DY et al: Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat (2002) 20:235.
137. Meindl A: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer (2002) 97:472-480.
138. Real FX, Malats N, Lesca G, Porta M, Chopin S, Lenoir GM, Sinilnikova O: Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut (2002) 50:653-657.
139. Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Gronberg H: Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer (2002) 98:838-843.
140. Lei H, Sjoberg-Margolin S, Salahshor S, Werelius B, Jandakova E, Hemminki K, Lindblom A, Vorechovsky I: CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer (2002) 98:199-204.
141. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA: Mutational analysis of selected genes in the TGFβ, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci (2002) 43:2845-2851.
142. Hamaguchi M, Meth JL, Von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH: DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA (2002) 99:13647-13652.
143. Taniguchi K, Yang P, Jett J, Bass E, Meyer R, Wang Y, Deschamps C, Liu W: Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clin Cancer Res (2002) 8:1115-1120.
144. Sossey-Alaoui K, Kitamura E, Head K, Cowell JK: Characterization of FAM10A4, a member of the ST13 tumor suppressor gene family that maps to the 13q14.3 region associated with B-cell leukemia, multiple myeloma, and prostate cancer. Genomics (2002) 80:5-7.
145. Yang P, Yokomizo A, Tazelaar HD, Marks RS, Lesnick TG, Miller DL, Sloan JA, Edell ES, Meyer RL, Jett J et al: Genetic determinants of lung cancer short-term survival: The role of glutathione-related genes. Lung Cancer (2002) 35:221-229.
146. Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M: Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations. J Mol Diagn (2001) 3:158-163.
147. Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W: Papillary renal cell carcinoma: Analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test (2001) 5:101-106.
148. Baldinu P, Cossu A, Manca A, Satta MP, Pisano M, Casula M, Dessole S, Pintus A, Tanda F, Palmieri G: Microsatellite instability and mutation analysis of candidate genes in unselected Sardinian patients with endometrial carcinoma. Cancer (2002) 94:3157-3168.
149. Kurzawski G, Suchy J, Kladny J, Safranow K, Jakubowska A, Elsakov P, Kucinskas V, Gardovski J, Irmejs A, Sibul H et al: Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States. J Med Genet (2002) 39:E65.
150. Nishioka M, Kohno T, Tani M, Yanaihara N, Tomizawa Y, Otsuka A, Sasaki S, Kobayashi K, Niki T, Maeshima A et al: MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci USA (2002) 99:12269-12274.
151. Varon R, Gosse-Brun S, Bignon YJ, Sperling K, Uhrhammer N: Nijmegen breakage syndrome gene (NBS1) is not the tumor suppressor gene at 8q21.3 involved in colorectal carcinoma. Oncol Rep (2002) 9:709-711.
152. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G et al: A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 71:981-984.